Effects of Chinese traditional compound, JinSanE, on expression of TGF-β1 and TGF-β1 type II receptor mRNA, Smad3 and Smad7 on experimental hepatic fibrosis in vivo

Table 1 Comparison of semiquantitative RT-PCR results in the four experimental groups (mean±SD).

Groups	n	Expression levels
		TGFβ1 mRNA	TRII mRNA
Normal	18	0.401±0.059	0.275±0.027
Model	15	1.410±0.094b	1.215±0.079b
JinSanE I	17	0.590±0.053d	0.461±0.029d
JinSanE II	16	0.693±0.057bd	0.651±0.035bdf

^bP<0.01 vs compared with the normal group;

^dP<0.01 vs compared with the model group; and

^fP<0.01 vs compared with JinSanE group I.

Table 2 Biochemical data in the four experimental groups (mean±SD).

Groups	n	ALT (IU/L)	AST (IU/L)	ALB (g/L)	A/G	HA (ng/L)
Normal rats	18	50.17±2.37	77.8±13.36	35.4±1.5	1.30±0.09	116.04±17.81
Model rats	15	276.0±45.4b	554.8±68.3b	24.7±3.15b	0.57±0.48b	318.65±20.83b
JinSanE I rats	17	105.3±15.1bd	331.5±47.9bd	30.1±2.3bd	0.89±0.04bd	138.20±11.39d
JinSanE II rats	16	109.5±28.5bd	248.5±9.42bd	32.7±1.8bd	0.94±0.07bd	129.50±17.04d

ALT, alanine transaminase; AST, aspartate transaminase; ALB, albumin; A/G, albumin/globulin ratio; and HA, hyaluronic acid.

^bP<0.01 vs compared with the normal group;

^dP<0.01 vs compared with the model group.

Table 3 Effects of JinSanE on liver necroinflammatory scores and fibrosis scores in the four experimental groups (mean±SD).

Groups	n	Necroinflammatory scores	Fibrosis scores
Normal	18	0	0
Model	15	5.28±1.31	7.44±1.59
JinSanE I	17	3.18±0.95a	4.40±1.27a
JinSanE II	16	4.05±0.92bc	5.57±1.20b

^bP<0.01 vs compared with the model group;

^aP<0.05 vs compared with the model group; and

^cP<0.05 vs compared with JinSanE group I.